A Phase 1 Study of ABBV-324 in People With Hepatocellular Cancer

Full Title

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-324 in Adults with Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

Purpose

Researchers are seeking the best dose of ABBV-324 to use in people with advanced hepatocellular carcinoma (HCC or liver cancer). The people in this study have HCC that is inoperable (cannot be surgically removed) or has metastasized (spread).

ABBV-324 is a type of drug called an antibody-drug conjugate (ADC). ADCs are composed of an antibody made from a specific cell line chemically linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and destroys them, with a lower risk of harming other cells. ABBV-324 is given intravenously (by vein).

Contact

For more information about this study or to see if you can join, please call Dr. Ghassan Abou-Alfa’s office at 646-888-4184.